A play in genetic research

I'm fascinated by genetic research and especially the National Geographic Genome project.  I can't get enough of this stuff and here is a company right in the middle of it all: Exelixs ( EXEL) and it's making money at it too.  Their big discovery is XL184 a promising compound for the treatment of oncological cancers

Exelixis Inc. (EXEL) is a leader in the fields of model system genetics and comparative genomics. These fields involve the systematic study of simple organisms, such as fruit flies, nematodes, mice, zebra fish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.

Technical Factors:

• 100% Barchart technical buy signal
• Trend Spotter (tm) buy signal
• 10 new highs and up 43.74% in the last month
• Relative strength Index is 79.98% and climbing
• Trades around 22.40 with a 50 day moving average of 9.01

Fundamental Factors:

• Wall Street brokerage analysts have published 4 buy and 3 hold reports
• Revenue is expected to increase by 5.30% next year
• Earnings are projected to increase by 22.40% this year and 22.70% next year

Investor sentiment:

• A surprising number of general investors have discovered this small stock
• On Motley Fool CAPS members vote 2,387 to 96 that the stock will out perform the market
• The more experienced All Stars agree 915 to 21
• Fool notes that Wall Street columnists have written 4 positive articles about the company

Jim Van Meerten is an analyst for  Marketocracy Capital Management.  He shares his knowledge and experience from over 40 years of investing in stocks, mutual funds and ETFs on Barchart.com  in his daily blog -- Barchart Portfolio Blogs.

Through Marketocracy Capital Management  you can have a Separately Managed Account that mirrors his Barchart Van Meerten New High model portfolio.